Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metastatic cancer

Metastatic cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metastatic cancer

64 trials tracked for Metastatic cancer: 9 in phase 3 or 4 and 6 with published results. The most-cited published study has 1660 citations.

64Trials tracked
9Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 3 9 Phase 2 37 Phase 1 12 Other / NA 6
  1. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,660 cited
  2. Phase 3 Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery Completed · 1,192 cited
  3. Phase 3 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed · 943 cited
  4. Phase 3 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed · 333 cited
  5. Phase 3 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Completed · 265 cited
  6. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
Show 44 more trials
  1. Phase 3 Octreotide in Treating Patients With Cancer-Related Malignant Ascites Completed
  2. Phase 3 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed
  3. Phase 3 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Completed
  4. Phase 2 Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy Completed
  5. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  6. Phase 2 Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer Completed
  7. Phase 2 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis Completed
  8. Phase 2 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Completed
  9. Phase 2 Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  10. Phase 2 Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer Completed
  11. Phase 2 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer Completed
  12. Phase 2 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
  13. Phase 2 Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases Completed
  14. Phase 2 SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial Completed
  15. Phase 2 Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases Completed
  16. Phase 2 S0916, MLN1202 in Treating Patients With Bone Metastases Completed
  17. Phase 2 S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone Completed
  18. Phase 2 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Completed
  19. Phase 2 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment Completed
  20. Phase 2 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Completed
  21. Phase 2 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Completed
  22. Phase 2 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed
  23. Phase 2 A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors Completed
  24. Phase 2 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer Completed
  25. Phase 2 Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer Completed
  26. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  27. Phase 2 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease Completed
  28. Phase 2 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma Completed
  29. Phase 2 Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Completed
  30. Phase 2 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Completed
  31. Phase 2 Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed
  32. Phase 2 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Completed
  33. Phase 2 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver Completed
  34. Phase 2 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer Completed
  35. Phase 2 Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases Completed
  36. Phase 2 Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases Completed
  37. Phase 2 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Completed
  38. Phase 2 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer Completed
  39. Phase 2 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations Completed
  40. Phase 2 QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Completed
  41. Phase 1 A Study of LY3007113 in Participants With Advanced Cancer Completed
  42. Phase 1 A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers Completed
  43. Phase 1 Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Completed
  44. Phase 1 Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis Completed

Showing the 50 most-cited and recently-updated of 64 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Metastatic cancer: what the trials found

Newer evidence includes the use of Pembrolizumab in metastatic cancer settings [2, 19]. Other established interventions include the use of AMG 479 [8, 13] and INCAGN01876 [18, 22].

Radiation therapies show varying outcomes. Stereotactic radiosurgery demonstrated significantly higher local control of the surgical bed compared to WBRT (87.1% vs 80.4%, p=0.00068) and a statistically significant difference in cognitive deterioration-free survival 4. External beam radiation therapy did not show a statistically significant difference in pain response at 3 months or over two years 7.

Pharmacological interventions for specific metastatic conditions include zoledronic acid, which showed no significant difference in time to skeletal-related events (SRE) 10 or time to first SRE 11, and no significant impact on overall survival [10, 11]. Octreotide acetate did not significantly improve the median time to paracentesis 9. Atrasentan hydrochloride combined with docetaxel and prednisone showed no significant difference in survival or progression-free survival compared to docetaxel and prednisone alone 6.

Regarding neurocognitive outcomes, Memantine was associated with a statistically significant difference in the median time to neurocognitive failure (2.6 vs 2.3, p=0.01) 5.

Recent results — preliminary, needs further review

  • Durvalumab is being evaluated in Phase 2 trials 1.
  • Checkpoint blockade immunotherapy is under investigation in Phase 2 trials 12.

For the clinician treating this condition

  • Stereotactic radiosurgery provides superior local control of the surgical bed compared to WBRT and shows significant differences in cognitive deterioration-free survival 4.
  • Zoledronic acid did not demonstrate statistically significant improvements in time to skeletal-related events or overall survival in metastatic settings [10, 11].
  • Atrasentan hydrochloride showed no significant difference in progression-free survival or overall survival when added to docetaxel and prednisone for hormone refractory prostate cancer 6.

AI synthesis of 9 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
EHR-facilitated collaborative care intervention increased initial palliative care consults by 50% in metastatic cancer patients
Palliative Care RCT
EHR-facilitated collaborative care intervention increased initial palliative care consults by 50% in metastatic cancer patients EHR symptom monitoring boosts palliative care visits for metastatic cancer patients
This secondary analysis of a cluster-randomized pragmatic trial evaluated an EHR-facilitated collaborative care intervention for monitoring …
A large trial shows that using electronic health records to track symptoms led to a 50% increase in palliative care visits for patients with…
Jun 1, 2026